Receptos Priced, Nasdaq: RCPT
Biotech developing treatments for relapsing multiple sclerosis and IBD.
Industry: Health Care
First Day Return: 0.0%
RCPT
Biotech developing treatments for relapsing multiple sclerosis and IBD.
| IPO Data | |
|---|---|
| IPO Date | 05/08/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $73 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | San Diego, CA, United States |
| Founded | 2008 |
| Employees at IPO | 36 |
| Website www.receptos.com | |
IPO News for Receptos
Receptos (RCPT) Performance
